Potassium Binders

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	**DD** – Drug-Drug Interaction	**MD** – Maximum Dose Limit	**TD** - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	**DS** Maximum Days' Supply Allowed	**PR** – Enrollment in a Physician-Supervised Program Required	**UN** – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	**DT** – Duration of Therapy Limit	**PU** – Prior Use of Other Medication is Required	**X** – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	**DX** – Diagnosis Code Requirement	**QL** – Quantity Limit	**YQ** – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	**ER** – Early Refill	**RX** – Specific Prescription Requirement	

Potassium Binders

POS Edits
CL – Additional clinical information (prescriber specialty, diagnosis, etc.) is required for patiromer (Veltassa®) ~~and sodium zirconium cyclosilicate (Lokelma®).~~
QL – Patiromer (Veltassa®) has a quantity limit of 30 packets per 30 days.

Revision / Date	Implementation Date
Created POS Document	July 2021
Removed clinical requirement for Lokelma / May 2023	July 2023